Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hem101 in Relapsed or Refractory B-cell Lymphoproliferative Disorders
NCT06705530Phase 2Completed
- Sponsor
- National Medical Research Center for Hematology
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Hem101 in B-cell lymphoproliferative disorder, acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), sponsored by National Medical Research Center for Hematology. Started Nov 2024; status: completed.
02
Drugs
Hem101
03
Conditions
B-cell lymphoproliferative disorderacute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06705530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705530.